Synonyms: SKLB-1028 | SKLB1028
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for ruserontinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase inhibitor and antineoplastic. Ruserontinib appears to be CSPC ZhongQi Pharmaceutical's oral multikinase inhibitor SKLB1028, which inhibits of EGFR, FLT3 and Abl [1], and is active against FLT3-driven malignancies and those with mutated Abl kinase proteins.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
ruserontinib (SKLB1028) has advanced to clinical evaluations in solid tumours and haematological malignancies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05072522 | A Study of SKLB1028 in Patients With Advanced Solid Tumor | Phase 1 Interventional | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | ||
NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated | Phase 3 Interventional | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |